41 related articles for article (PubMed ID: 38644245)
1. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Arak H; Erkiliç S; Yaslikaya Ş; Eylemer Mocan E; Aktaş G; Özdemir M; Semiz HS; Kiliçkap S; Özalp FR; Sever ÖN; Akdağ G; Ağaoğlu AB; Özçelik M; Sari M; Arcagök M; Anik H; Yayla ŞB; Sever N; Açar FP; Bayrakçi İ; Turhal S; Ayhan M; Kuş T;
J Immunother; 2024 Jun; 47(5):182-189. PubMed ID: 38333962
[TBL] [Abstract][Full Text] [Related]
3. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis.
Huang X; Fang J; Huang L; Chen H; Chen H; Chai T; Ye Z; Chen H; Xu Q; Du Y; Yu P
Gastric Cancer; 2023 Nov; 26(6):1040-1050. PubMed ID: 37768447
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.
Wang K; Yu Y; Zhao J; Meng Q; Xu C; Ren J; Zhang Y; Wang Y; Wang G
Curr Gene Ther; 2024; 24(2):147-158. PubMed ID: 37767800
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
Balmaceda NB; Kim SS
J Gastrointest Cancer; 2024 Mar; 55(1):153-167. PubMed ID: 38127239
[TBL] [Abstract][Full Text] [Related]
6. Interpretable machine learning for predicting the response duration to Sintilimab plus chemotherapy in patients with advanced gastric or gastroesophageal junction cancer.
Wang DQ; Xu WH; Cheng XW; Hua L; Ge XS; Liu L; Gao X
Front Immunol; 2024; 15():1407632. PubMed ID: 38840913
[TBL] [Abstract][Full Text] [Related]
7. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y; Yoshida K; Kochi M; Sano T; Ichikawa W; Kakeji Y; Sunakawa Y; Takeuchi M; Fujii M
Gastric Cancer; 2023 Nov; 26(6):1063-1068. PubMed ID: 37548812
[TBL] [Abstract][Full Text] [Related]
8. 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Nomura T; Hato S; Choda Y; Yabusaki H; Yoshida K; Misawa K; Masuzawa T; Tsuda M; Kawachi Y; Katayama H; Fukuda H; Kurokawa Y; Boku N; Sano T; Sasako M
Gastric Cancer; 2024 Jan; 27(1):155-163. PubMed ID: 37989806
[TBL] [Abstract][Full Text] [Related]
9. An On-Treatment Decreased Trend of Serum IL-6 and IL-8 as Predictive Markers Quickly Reflects Short-Term Efficacy of PD-1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer.
Liu J; Mao Y; Mao C; Wang D; Dong L; Zhu W
J Immunol Res; 2024; 2024():3604935. PubMed ID: 38774604
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Interstitial Pneumonia Induced by Immune Checkpoint Inhibitors for Gastric Cancer During the COVID- 19 Pandemic].
Yasuda K; Naito M; Kawakami K; Kishimoto A; Narita K; Moriwaki Y; Otani J
Gan To Kagaku Ryoho; 2024 Apr; 51(4):466-469. PubMed ID: 38644324
[TBL] [Abstract][Full Text] [Related]
11. Deep learning based digital pathology for predicting treatment response to first-line PD-1 blockade in advanced gastric cancer.
Liu Y; Chen W; Ruan R; Zhang Z; Wang Z; Guan T; Lin Q; Tang W; Deng J; Wang Z; Li G
J Transl Med; 2024 May; 22(1):438. PubMed ID: 38720336
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer].
Zhu ZG
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1331-1336. PubMed ID: 38644278
[TBL] [Abstract][Full Text] [Related]
13. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Janjigian YY; Sanchez-Vega F; Jonsson P; Chatila WK; Hechtman JF; Ku GY; Riches JC; Tuvy Y; Kundra R; Bouvier N; Vakiani E; Gao J; Heins ZJ; Gross BE; Kelsen DP; Zhang L; Strong VE; Schattner M; Gerdes H; Coit DG; Bains M; Stadler ZK; Rusch VW; Jones DR; Molena D; Shia J; Robson ME; Capanu M; Middha S; Zehir A; Hyman DM; Scaltriti M; Ladanyi M; Rosen N; Ilson DH; Berger MF; Tang L; Taylor BS; Solit DB; Schultz N
Cancer Discov; 2018 Jan; 8(1):49-58. PubMed ID: 29122777
[TBL] [Abstract][Full Text] [Related]
14. Effective control of postoperative recurrence of pregnancy-related gastric cancer using anti-PD-1 as a monotherapy: a case report.
Liu X; Li X; Zhu C; Ji L
Front Oncol; 2024; 14():1321149. PubMed ID: 38800370
[TBL] [Abstract][Full Text] [Related]
15. Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.
Kim HD; Ryu MH; Lee JS; Kang YK
Gastric Cancer; 2024 Apr; ():. PubMed ID: 38602609
[No Abstract] [Full Text] [Related]
16. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
17. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
18. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
19. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]